Generate Biomedicines IPO
NASDAQ: GENB
Generate Biomedicines completed their IPO on February 27, 2026. Now that Generate Biomedicines is a public company, Nasdaq Private Market does not actively track its performance. The data below is for reference before the company’s IPO.
Generate Biomedicines is pioneering the field of generative biology with a revolutionary approach to drug development that allows them to program protein-based modalities for the first time.
Sign up for SecondMarket® to invest in or sell private companies like Generate Biomedicines before their IPO.
Buy + SellGenerate Biomedicines Stock Price Chart Before IPO
The below graph shows the estimated historical Generate Biomedicines stock price prior to their IPO on February 27, 2026, (known as the Tape D™ price). Prior to Generate Biomedicines going public their private stock value was based on market activity, publicly-sourced valuation data, and other proprietary information.
Generate Biomedicines Pre-IPO Stock Price Per Share
Generate Biomedicines Funding Pre-IPO
Gain insights into Generate Biomedicines funding history prior to their IPO, including the funding round, time period, and amount raised.
Sign Up to Unlock the Data| Financing Round | Date | Amount | Price per share* | Valuation* |
|---|---|---|---|---|
| Series C | Jan 12, 2024 | 280.95M | ||
| Series B | Nov 23, 2021 | 373.42M | ||
| Series A | Dec 31, 2019 | 30.10M |
See Generate Biomedicines Valuations + Financials
*Sample data + company shown for illustrative purposes only
Gain insights Into Generate Biomedicines Stock Valuation + Share Prices
View real-time Tape D® data on Generate Biomedicines stock including most recent valuation and historical share price information.
Are you an institutional investor or employee shareholder? Sign up to the SecondMarket trading platform.
Get Started
Generate Biomedicines Management Team - Prior to IPO
-
Board Member
Frances Arnold
-
Co-Founder, Chief Innovation Officer
Molly Gibson
-
Co-Founder, Director
Geoffrey von Maltzahn
-
Chief Legal Officer and General Counsel
Sean Martin
-
Board Member
Gary P. Pisano
-
Board Member
Jane Mendillo
-
Board Member
Stephane Bancel
-
Chief Financial Officer
Jason Silvers
-
Co-Founder, Chief Technology Officer
Gevorg Grigoryan
-
Chief People Officer
Beth Grous
-
Board Member
Noubar Afeyan
-
CEO, Director
Michael Nally
Generate Biomedicines Major Investors - Prior to IPO
-
Abu Dhabi Investment Authority (ADIA)
-
Banque Pictet
-
ARCH Venture Partners
-
T. Rowe Price
-
Amgen Ventures
-
Altitude Life Science Ventures
-
Morningside Venture Investments
-
Mirae Asset Financial Group
-
Fidelity
-
NVIDIA
-
Alaska Permanent Fund (APFC)
-
March Capital
-
Flagship Pioneering
Learn More About Generate Biomedicines Stock
Buy Generate Biomedicines Stock
01Generate Biomedicines became publicly traded following its IPO on February 27, 2026, its shares now trade on public stock exchanges under the ticker symbol NASDAQ: GENB. Before the IPO, Generate Biomedicines stock was privately held and available only through private market transactions.
If you’re an accredited investor looking to purchase pre-IPO shares in a private company, Nasdaq Private Market can help you get started. Learn more about investing in the private market or sign up for free to explore available opportunities. Learn more about how private company shares trade prior to an IPO on our investors page.
Sell Generate Biomedicines Stock
02Following its IPO on February 27, 2026, Generate Biomedicines shares trade on public stock exchanges, allowing shareholders to sell stock through a traditional brokerage.
If you currently hold shares in a private company, Nasdaq Private Market may be able to help you explore your sell private company stock. Our platform provides a secure and compliant way to sell your shares on terms that work for both you and the company. To understand how employees sell shares before a company goes public, visit the Employee Shareholders page.
Generate Biomedicines Stock Price
03Prior to the Generate Biomedicines IPO on February 27, 2026, Nasdaq Private Market Tape D pricing estimates the company’s share price at $5.17, reflecting market activity and valuation data from private markets.
Following the IPO, Generate Biomedicines stock prices can now be viewed publicly on major exchanges. Investors and interested parties can find the current stock price by searching Generate Biomedicines’s ticker symbol on financial platforms such as Nasdaq.com or through their preferred brokerage platform.
Generate Biomedicines Stock Ticker Symbol
04Following its IPO on February 27, 2026, Generate Biomedicines stock now trades on public markets under the ticker symbol NASDAQ: GENB. You can view real-time stock information through widely used financial data platforms.
Criteria to Sell Generate Biomedicines Stock
05Following the Generate Biomedicines IPO, public shares can be sold through any brokerage.
Nasdaq Private Market works with employees, ex-employees, and other private company shareholders of pre-IPO companies to sell their shares. The Nasdaq Private Market platform provides a secure and compliant way to sell your shares on terms that work for both you and the company. To learn more about how to sell private company stock, visit the Employee Shareholders page.
Read more about how to sell shares of a private company and eligibility for selling privately held stock:
Criteria to Buy or Invest in Generate Biomedicines Stock
06Following Generate Biomedicines’s initial public offering on February 27, 2026, its shares are now listed on a public exchange and available for purchase through a brokerage account. Investors interested in buying Generate Biomedicines stock can do so through their preferred broker, just as they would with any other publicly traded security.
Nasdaq Private Market continues to work with investors seeking exposure to private company opportunities prior to IPO. Through structured transactions and curated offerings, investors can participate in private market activity before companies enter the public markets.
Learn more about the Nasdaq Private Market tool kit for investors on the Investor Trading page.
Generate Biomedicines Stock Settlement
07Since Generate Biomedicines is now publicly traded, public-market share transfers and settlement occur automatically through a brokerage or exchange.
Nasdaq Private Market supports transfer and settlement for privately held company equity. In order to buy or sell private company stock, share ownership must transfer before funds are wired. With Nasdaq Private Market, clients leverage our patented Transfer and Settlement technology which streamlines and manages transfer activity from match to settlement.
To learn more about private company stock Transfer and Settlement, check out the Transfer and Settlement page.
Generate Biomedicines IPO
08Generate Biomedicines completed its IPO on February 27, 2026, and is now publicly available through major financial sources.
Sign up for SecondMarket® to invest in or sell private companies like Generate Biomedicines before their IPO.
Buy + Sell*All trademarks are the property of their respective owner(s). Unless expressly stated otherwise, companies listed on this site are not sponsoring, endorsing, or otherwise affiliated with, Nasdaq Private Market, LLC, and none of the statements on this website should be attributed to a listed company.
